News
Second patent granted for Ruthenium-based PDT cancer drugs
A second patent (US #9,676,806) has been granted for our high-potency photodynamic cancer drugs.
A second patent (US #9,676,806) has been granted for our high-potency photodynamic cancer drugs.
